Recent Updates
Recently added Catalysts
OM Positive Sentiment

Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026

Key Takeaway: Outset Medical, Inc. will announce its fourth quarter and full-year 2025 financial results on February 11, 2026. The announcement will be followed by a conference call hosted by CEO Leslie Trigg and CFO Renee Gaeta. The company is known for its innovative Tablo® Hemodialysis System, which aims to simplify dialysis processes.
Price reaction · baseline $4.97 (2026-01-26 close) · hit pre-market · 2 other OM headline(s) in the window, move may be shared
day 0 close · peak
+14.3%
day 1
+1.1%
day 3
+0.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Outset Medical is pioneering innovative technology for dialysis.
  • The Tablo® Hemodialysis System is FDA-cleared and widely trusted.
  • The upcoming financial results may indicate positive growth and performance.

Full Press Release Details

SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full-year 2025 after the close of trading on Wednesday, February 11, 2026.
On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results.
Conference Call DetailsThe conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Wednesday, February 11, 2026. Those interested in joining the conference call may do so byregistering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website athttps://investors.outsetmedical.com/.
About Outset Medical, Inc.Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visitwww.outsetmedical.com.

Frequently Asked Questions

When will Outset Medical report its Q4 2025 results?

Outset Medical will report its Q4 2025 financial results on February 11, 2026.

Who will host the conference call for the results?

Leslie Trigg, CEO, and Renee Gaeta, CFO, will host the conference call.

What technology does Outset Medical specialize in?

Outset Medical specializes in innovative dialysis technology, including the Tablo® Hemodialysis System.

How can participants join the conference call?

Participants can join by registering online to receive dial-in numbers and a unique pin.

Last updated: Jan 27, 2026